ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY...
-
Upload
nathan-gibbs -
Category
Documents
-
view
218 -
download
1
Transcript of ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY...
![Page 1: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/1.jpg)
ANNA Meeting, Nov 2013
Kenar D. Jhaveri, M.DHofstra North Shore LIJ School of
Medicine, [email protected]
![Page 2: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/2.jpg)
The field of nephrology that is deals with complications of a cancer.
![Page 3: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/3.jpg)
Kidney disease either pre existing or developing in the course of the cancer
New Glomerular paraneoplastic disease Obstructive Nephropathy Tubular interstitial Damage Thrombotic microangiopathy Radiation Nephropathy Tumor invasion of the kidney Tumor lysis syndrome Multiple Myeloma Fluid and electrolyte disorders Decision regarding renal replacement therapy
![Page 4: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/4.jpg)
Which ONE of the following statements is correct regarding the risk of malignancy in patients with ESRD?
![Page 5: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/5.jpg)
A.There is a 5% increase in the risk of malignancy in patients with ESRDB.The commonest form of cancer found in patients with ESRD is lung cancerC.The risk of bladder cancer rises with increased time on dialysisD.The risk for kidney cancer rises with increased time on dialysis.
![Page 6: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/6.jpg)
1. The overall risk of cancer is increased in patients with ESRD, and the distribution of tumor types resembles the pattern seen after transplantation.
2. The overall risk for cancer in this population of ESRD patients is approximately 20%.
3. Renal parenchymal cancers are increased in all categories of primary renal disease, and the risk rises with time on dialysis treatment.
4. Cancers of the lung, colorectum, prostate, breast, and stomach were not consistently increased in patients on dialysis.
![Page 7: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/7.jpg)
During a median follow up around 13 years, 370 cancer deaths were observed in study cohort.
For every 10-mL/min/1.73m2 reduction in eGFR, there was an increase in cancer-specific mortality of 18% in the fully adjusted model.
This excess cancer mortality varied with site, with the greatest risk for breast and urinary tract cancer deaths
Iff S et al. Reduced estimated GFR and cancer mortality. AJKD 2013 in press.
![Page 8: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/8.jpg)
Know that CKD and ESRD patients are at higher risk of cancer than general population.
Screening? – would you advocate?
![Page 9: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/9.jpg)
A 68 Y old Female with Laryngeal cancer received chemotherapy with cisplatin. Five days later, CRT is 5.0, Na is 132, and mg is 0.3. Urine Na is high
Cisplatin is stopped and renal function normalizes.
What orders will the nephrologists give you to help prevent this injury next time this patients gets cisplatin?
![Page 10: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/10.jpg)
Flombaum Cancer and the kidney,chap 6
![Page 11: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/11.jpg)
![Page 12: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/12.jpg)
Ms Jem Sitaben is a 70 y.o. female with Pancreatic cancer treated with DRUG Z ( cumulative dose 21,750 mg/m2) referred to Renal service for poorly controlled HTN. BP 150/80 treated with Amlodipine, Atenolol and Furosemide.
CBC and crt normal at that time repeat renal consultation-ARF Hgb 9.7; Plt 49; Creat 1.9; LDH 553; Haptoglobin <6; U Prot
300+ Creat remained stable at 2.0, offending agent was stopped.
Patient died from pancreatic disease progression
![Page 13: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/13.jpg)
Mitomycin C is associated with Hemolytic Uremic Syndrome (HUS) at total cumulative doses above 40-60 mg/m2
HUS usually occurs within 4-8 weeks after the last dose and carries a poor prognosis
![Page 14: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/14.jpg)
![Page 15: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/15.jpg)
Gemcitabine is a nucleoside analog with antineoplastic activity against a variety of solid tumors including pancreatic, non-small cell lung, bladder, ovarian and breast carcinomas
Mild proteinuria and microscopic hematuria may occur in up to 50% of pt treat with Gemcitabine
HUS is a well-described complication with an incidence of 0.31%-0.4%
![Page 16: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/16.jpg)
The presentation is subacute with insidious onset of renal dysfunction, hemolytic anemia, new or worsening hypertension and thrombocytopenia
Unrecognized, progression to fulminant acute renal failure and hypertensive crisis can occur
Useful Lab data: LDH, Haptoglobin, Smear Review, Reticulocyte Count, Creat, Urinalysis
![Page 17: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/17.jpg)
![Page 18: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/18.jpg)
CHEMOTHERAPY may be nephrotoxic Many newer agents have many renal side effects and be vigilant as you see some of these patients!
![Page 19: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/19.jpg)
![Page 20: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/20.jpg)
Patient Specific Factors Kidney Specific Factors Drug Specific Factors
![Page 21: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/21.jpg)
Kidney Pathology 101
GlomeruliTubulesInterstitiumVasculature
![Page 22: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/22.jpg)
![Page 23: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/23.jpg)
Agents known to be nephrotoxic
CisplatinumMethotrexateGemcitabineCalcineurin InhibitorsBisphosphanatesTyrosine Kinase Inhibitors Anti VEGF agents
![Page 24: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/24.jpg)
![Page 25: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/25.jpg)
Mr. Tumor has lung cancer( NSCLC). His serum calcium is 14.
The patient is in acute renal failure as well. The Nephrologist initiated dialysis for the hypercalcemia induced AKI
What is causing the high calcium? How can you medical treat that? Before dialysis?
![Page 26: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/26.jpg)
Imatinib (mTKI) induces hypophosphatemia◦ inhibition of platelet-derived growth factor receptor expressed on
osteoclasts ◦ subsequent decreased bone resorption◦ decreased calcium, and phosphate egress from the bone◦ PTH levels (due to decreased calcium egress) and further renal
phosphate wasting Cetuximab/Panitumumab-EGFR antibody
◦ Hypomagnesemia-due to renal wasting◦ Possible inhibition of TRPM6 cation channel
Berman E., et al. N Engl J Med 2006;354:2006-13.Berman E., et al. N Engl J Med 2006;354:2006-13.Schrag D., et al. JNCI, Vol. 97, No. 16, August 17, 2005Schrag D., et al. JNCI, Vol. 97, No. 16, August 17, 2005
![Page 27: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/27.jpg)
Hypomagnesemia incidence of 1.8-5.8% in initial trials Higher incidence when measured more rigorously Duration of therapy, age and baseline Mg IV repletion required Calcium and Potassium repletion also required Improves/resolves appox 4-6 weeks after stopping agent ? Role of Amiloride
Fakih et al, Clin C Can 2006.
Vij R, Sachdeva M. NKF 2010 Abstract
![Page 28: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/28.jpg)
![Page 29: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/29.jpg)
![Page 30: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/30.jpg)
Hyponatremia, hypernatremia Hypercalcemia Hypomagnesemia Hypokalemia and hyperkalemia
All have been discovered and be vigilant of that as well.
![Page 31: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/31.jpg)
A 56 y old male with IgG kappa myeloma develops proteinuria. A kidney biopsy reveals nodular sclerosis. Congo red staining is negative. What is the patho-physiology of the pathology found on kidney biopsy?
A. Nephrin injury B. Endothelial damage C. Mesangial cell injury D. Fibril formation causing glomerular damage.
![Page 32: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/32.jpg)
![Page 33: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/33.jpg)
Abnormal, usually excessive, synthesis of immunoglobulin molecules or subunits.
Result from clonal proliferations of plasma cells or B lymphocytes.
Majority of cases are caused by plasma cell proliferations rather than B-cell lymphoproliferative disorders.
![Page 34: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/34.jpg)
Prevalence ◦ MGUS 3.2% in people over 50◦ Myeloma 13% of all hematologic cancers
Renal Manifestations◦ In a minority of patients paraprotein are pathogenic◦ 3% of native kidney biopsies diagnose a paraprotein related disease
Presentation ◦ Proteinuria and/or renal failure
Treatment◦ Reducing the supply of paraprotein◦ Supporting or replacing compromised organ function
Outcome on dialysis is poor◦ Compared with other disease groups, 2-year survival is about 30% less.◦ Response to chemotherapy equal but difficult to administer
![Page 35: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/35.jpg)
TUBULAR◦ Cast nephropathy◦ Light chain Fanconi syndrome
GLOMERULAR◦ Amyloidosis◦Monoclonal immunoglobulin deposition disease (MIDD)◦ Immunotactoid and fibrillary glomerulonephritis◦ Cryoglobulinemic glomerulonephritis◦ Waldenstroms macroglobulinemic glomerulonephritis◦ Proliferative glomerulonephritis and monoclonal
immunoglobulin deposits
![Page 36: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/36.jpg)
Free light chains are freely filtered.
Reabsorbed and catabolized by proximal tubular epithelial cells.
When the light chains in the tubular filtrate exceed the maximal reabsorptive capacity of the proximal tubule.◦ precipitate, producing light chain
cast nephropathy (myeloma kidney)
◦ remain in the tubular filtrate resulting in light chain proteinuria.
![Page 37: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/37.jpg)
Cast nephropathy
MIDD
AL amyloidosis
Solomon et al NEJM 1991
Cast nephropathy
MIDD
AL amyloidosis
![Page 38: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/38.jpg)
Clinical scenario◦ Known paraprotein with renal
dysfunction/proteinuria◦ Renal dysfunction/proteinuria
and anemia◦ Dipstick negative with high p/c
ratio Clinical features cannot
distinguish among the various patterns of renal disease associated with dysproteinemias.
Renal biopsy is necessary to establish the individual diagnosis.
![Page 39: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/39.jpg)
Treat the acute situation◦ Optimize hemodynamics and intravascular volume◦ Treat hypercalcemia aggressively
IV saline Bisphosphonates
◦ Avoid nephrotoxins Decrease the production of paraproteins
![Page 40: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/40.jpg)
Light chain cast nephropathy (also known as myeloma kidney).
Heher E C et al. CJASN doi:10.2215/CJN.12231212
©2013 by American Society of Nephrology
![Page 41: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/41.jpg)
A 89 year old male on HD for cardiac related renal disease from heart failure now gets diagnosed with mets from prostate cancer. He has been on dialysis for 2 years. He reads a NY Times article on withdrawal of dialysis and cost to the society and comes to his nephrologist and says, “ I have lived my life- please withdraw me from dialysis”. What does the nephrologist do?
Call a psychiatry consult Arrange a family meeting with social worker as well Discuss the reasons why the patient want’s to come off
dialysis Arrange for end of life care services and agree with the
patient’s wishes.
41
![Page 42: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/42.jpg)
When Ailments Pile Up, Asking Patients to Rethink Free Dialysis
By GINA KOLATA Published: March 31, 2011
42
![Page 43: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/43.jpg)
Rising median age of dialysis population
48% > 65 yrs old Over 72,000 dialysis patients
die per year ~20% die after decision to
withdraw High percentage with
comorbidities High in-hospital death (61% in
one study) Unknown but low % die with
hospice
![Page 44: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/44.jpg)
“Most patients with ESRD, especially those who are not candidates for renal transplantation, have a
significantly shortened life expectancy.”
44
![Page 45: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/45.jpg)
Average of 17 deaths per dialysis unit/yr 78% of units withdrew at least 1 patient
(1990) Mean # withdrawn: 3 (0-20) Most nephrologists withdraw at least one
patient/yr Mean # withdrawn/nephrologist/yr: 3 (0-
10) (1995)
45
![Page 46: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/46.jpg)
• Unacceptable quality of life (failure to thrive)
• Acute complication• Dementia• Stroke•Cancer• Other
46
![Page 47: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/47.jpg)
Lack of education, especially of nephrologists Unwillingness of dialysis corporations to respect dialysis
patients’ preference for DNR order Patient/family denial of permanent nature of ESRD Lack of patient awareness of life-limiting nature of ESRD
resulting in many not wanting to discuss end-of-life issues
![Page 48: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/48.jpg)
A 45 year old with metastatic renal cancer is admitted to the intensive care unit. The patient has failed all possible treatments for renal cancer including tyrosine kinase inhibitors, IL-2 agents, and research protocols. He is admitted for acute shortness of breath and quickly intubated for ARDS. Two days into his course, he develops oliguric acute renal injury and septic shock requiring three pressor support medications. A renal consult is called to offer CVVHDF. Nephrology team #1 offers the therapy. Nephrology team #2 is consulted for a second opinion. Nephrology team #2 is consulted and a “surprise question” is asked and dialysis is not offered to the patient.
Which consult team is giving appropriate care? Which consult team is treating the family ? Which consult team is treating the “lawyers”?
![Page 49: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/49.jpg)
The Surprise Question: “Would I be surprised if this patient dies in the next year?”◦ Estimate of prognosis is based upon patient’s
age, functional status, medical condition, including comorbidity and recent sentinel events, and this “surprise” question
◦ Surprise question prognostic tool is available online: http://touchcalc.com/calculators/sq
◦ There is not the same degree of precision of tools to estimate prognosis for patients with AKI
![Page 50: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/50.jpg)
Recommendation No. 7: Special Patient Groups It is reasonable to consider not initiating or withdrawing
dialysis for patients with ARF or ESRD who have a terminal illness from a non-renal cause or whose medical condition precludes the technical process of dialysis.
50
![Page 51: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/51.jpg)
51
Type of careDialysis patients Cancer patients
Hospitalization 76.0% 61.3%
Average number of days hospitalized
9.8 5.1
Intensive care unit
48.9% 24.0%
Average number of days in ICU
3.5 1.3
Ventilator, feeding tube or CPR
29.0% 9.0%
Hospice 20.0% 55.0%
In-hospital death
44.8% 29.0%
![Page 52: ANNA Meeting, Nov 2013 Kenar D. Jhaveri, M.D Hofstra North Shore LIJ School of Medicine, NY kjhaveri@nshs.edu.](https://reader036.fdocuments.in/reader036/viewer/2022062518/56649de75503460f94ae01f5/html5/thumbnails/52.jpg)
Oncology Nephrology
Pharmacy
ONCO
Nephrology